A Study to Examine Anktiva for the Treatment of COVID-19.
Trial details
- Registry ID
- NCT07123727
- Phase
- Phase 2
The FDA approved Anktiva (N-803) on 22 Apr 2024.
Drug identity checked against registry records
Also recorded as N-803; NAI; Nogapendekin Alfa Inbakicept
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Examine Anktiva for the Treatment of COVID-19.NCT07123727 | IBRX | Phase 2 | Recruiting | 2027-03Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2024-04-22Day | Anktiva | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA761336", "applicant_as_listed_by_fda": "ALTOR BIOSCIENCE, LLC, AN INDIRECT WHOLLY-OWNED SU", "brand_names": ["ANKTIVA"], "active_ingredients": ["nogapendekin alfa inbakicept-pmln"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20240422", "matched_on": "drug name equals FDA brand name"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |